As we shared in a recent blog, VetStem launched a human stem cell company known as Personalized Stem Cells, Inc (PSC) in late 2018.  PSC was founded to advance and legitimize human regenerative medicine through FDA approved clinical trials.  As such, it was announced in June that PSC submitted their first FDA-IND (“Investigational New Drug”) application for the treatment of osteoarthritis, with the first clinical trial to be for patients with OA in the knee.

In less than one year since the company’s formation, PSC recently announced that their application was approved for conducting clinical trials for the treatment of osteoarthritis using stem cells.  The fast approval was in large part due to VetStem’s extensive experience and data from stem cell therapy in the veterinary field.

This is the first of several planned INDs that PSC will seek FDA approval for.  Similar to the VetStem model, they plan to start with orthopedic conditions and eventually expand to include other medical conditions.  Like VetStem, PSC will follow strict quality control and safety protocols.

For the first clinical trial, PSC has enrolled a limited number of clinical sites around the U.S. to provide treatment for knee osteoarthritis using stem cells. The enrolled physicians are among the most experienced stem cell physicians in the country.  You can contact PSC for clinical trial information, clinical trial site locations, or investment information.